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Abstract 
Background: Short QT syndrome (SQTS) is a newly identified clinical disorder associ-
ated with atrial and/or ventricular arrhythmias and increased risk of sudden cardiac 
death (SCD). The SQTS variant 3 is linked to D172N mutation to the KCNJ2 gene that 
causes a gain-of-function to the inward rectifier potassium channel current (IK1), which 
shortens the ventricular action potential duration (APD) and effective refractory period 
(ERP). Pro-arrhythmogenic effects of SQTS have been characterized, but less is known 
about the possible pharmacological treatment of SQTS. Therefore, in this study, we 
used computational modeling to assess the effects of amiodarone, class III anti-arrhyth-
mic agent, on human ventricular electrophysiology in SQT3.
Methods: The ten Tusscher et al. model for the human ventricular action potentials 
(APs) was modified to incorporate IK1 formulations based on experimental data of Kir2.1 
channels (including WT, WT-D172N and D172N conditions). The modified cell model 
was then implemented to construct one-dimensional (1D) and 2D tissue models. The 
blocking effects of amiodarone on ionic currents were modeled using  IC50 and Hill 
coefficient values from literatures. Effects of amiodarone on APD, ERP and pseudo-ECG 
traces were computed. Effects of the drug on the temporal and spatial vulnerability of 
ventricular tissue to genesis and maintenance of re-entry were measured, as well as on 
the dynamic behavior of re-entry.
Results: Amiodarone prolonged the ventricular cell APD and decreased the maxi-
mal voltage heterogeneity (δV) among three difference cells types across transmural 
ventricular wall, leading to a decreased transmural heterogeneity of APD along a 1D 
model of ventricular transmural strand. Amiodarone increased cellular ERP, prolonged 
QT interval and decreased the T-wave amplitude. It reduced tissue’s temporal suscepti-
bility to the initiation of re-entry and increased the minimum substrate size necessary 
to sustain re-entry in the 2D tissue.
Conclusions: At the therapeutic-relevant concentration of amiodarone, the APD and 
ERP at the single cell level were increased significantly. The QT interval in pseudo-ECG 
was prolonged and the re-entry in tissue was prevented. This study provides further 
evidence that amiodarone may be a potential pharmacological agent for preventing 
arrhythmogenesis for SQT3 patients.
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Background
Short QT syndrome (SQTS) is a potentially lethal cardiac ion channelopathy associ-
ated with a variety of signs and symptoms, from dizziness and fainting (syncope) to car-
diac arrest and sudden death [1–6]. These signs and symptoms can occur anytime from 
early infancy to old age. Among which, short QT interval in SQTS patients is commonly 
less than 360 ms, and T-wave morphology is tall and symmetrical. SQTS with various 
mutations is genetically heterogeneous, involving the KCNH2 [4], KCNQ1 [3], KCNJ2 
[2], CACNA1C [7], CACNB2b [7] and CACNA2D1 [8] genes. These identified gene 
mutations in membrane ion channels alter the electrical activity of the heart, leading 
to arrhythmic characteristic of SQTS. Among the mutations, either a gain-in-function 
of the potassium channel or a loss-in-function of the calcium channel across the mem-
brane of cardiac muscle cells has been observed [2–4, 7, 8].
The SQTS is associated with accelerated ventricular repolarization and with an 
increased risk of atrial and/or ventricular arrhythmias and of sudden cardiac death (SCD) 
[6, 9]. A gain-of-function KCNJ2 mutation has been identified in SQTS variant 3 (SQT3), 
with a 5-year-old child and her father exhibiting a corrected QT interval (QTc) of 315 and 
320 ms, respectively, and a narrow and peaked T-wave morphology on the clinical elec-
trocardiogram (ECG) [2]. Based on a systematic genetic analysis, a pair of complementary 
bases substituted from aspartic acid to asparagine at position 172 in the Kir2.1 channel 
was discovered. The results from in vitro voltage clamp recordings have demonstrated an 
increased IK1 in the Kir2.1 channels during terminal repolarization of the action poten-
tials (APs) [2]. Our previous computational studies [10] have shown that SQT3 abbrevi-
ated the AP duration (APD) and effective refractory period (ERP) and steepened APD 
restitution (APD-R) and ERP restitution (ERP-R) curves, which consequently shortened 
the QT interval and raised the T-wave amplitude. Whereas pro-arrhythmogenic effects 
of SQT3 in the human ventricles have been investigated [2, 10], less is known about the 
pharmacological agents that prevent incidence of arrhythmogenesis in SQT3 patients.
Currently, the only proven therapy for SQTS patients is the application of an electric 
shock, delivered via an implantable cardioverter defibrillator (ICD) [9, 11–13]. Despite 
the success of this technique, there is an increased risk of an inappropriate shock dis-
charged by the ICD [9, 11, 12, 14]. As the QT interval is not restored within the normal 
range over time, ICD is unsuitable for SQTS patients [12]. Although SQTS patients may 
benefit from subcutaneous ICD, additional cautions are needed to affirm the safety of 
such device [15]. To effectively treat SQTS patients, pharmacological therapy may be the 
primary modality to restore the normal QT interval and protect against arrhythmia [9, 
11, 16, 17]. However, data regarding pharmacological treatment of SQTS are very lim-
ited. A clinical study by Lu et al. [18] showed that amiodarone prevented the incidence 
of arrhythmia and prolonged the QT interval in an SQTS patient, but electrophysiologic 
testing data were not available in that patient. Long-term therapy of amiodarone may be 
associated with unwanted effects. Important side effects were seen in the thyroid gland, 
liver, lung and skin. Some of these side effects are dose-dependent, and others may be 
related to the chemical structure and metabolism of amiodarone [19]. At present, there 
is no experimental model of SQT3. Moreover, drugs exert effects spanning from the ion 
channel to the whole organ level, making investigation using experimental techniques 
tough and rather expensive [20]. In recent years, computational models of the heart are 
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beginning to play a critical role in the investigations of arrhythmias and anti-arrhythmic 
therapy. Therefore, this study was undertaken in order to assess the effects of amiodar-
one, a class III anti-arrhythmic agent, on human ventricular cell and tissue model in 
SQT3 conditions, and consequent effects of amiodarone on QT interval prolongation 
and prevention of re-entrant arrhythmia in this form of SQTS.
Methods
We proposed an assessment flow for evaluating the actions of amiodarone on ventricu-
lar excitation associated with SQT3 at the cell and tissue levels using mathematical mod-
els of the heart, as illustrated in Fig. 1.
IK1 kinetics and drug/ion current channel interaction
The ten Tusscher et  al. [21] model for human ventricular endocardial (ENDO), mid-
myocardial (MIDDLE) and epicardial (EPI) APs was used for this study. The parameters 
of IK1 model were modified to incorporate the experimentally observed kinetic proper-
ties of the wild-type (WT) and mutant homozygous (D172N) and heterozygous (WT-





xK1∞(V − EK )
Fig. 1 Computer-based assessment flowchart for testing amiodarone actions at hierarchical levels including 
ion channel, cellular and tissue. The actions of amiodarone on ventricular excitation associated with SQT3 at 
cell and tissue levels can be characterized by analyzing their effects on a family of biomarkers
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where V is the transmembrane voltage, EK is the potassium reversal potential, GK1 is the 
maximum conductance, and xk1∞ is a rectification factor, which is a characteristic of the 
open-up probability of the channel. The IK1 model used was that of ten Tusscher [21], 
which was based on the formulation of Priebe and Beuckelmann [22] model. Experi-
mentally obtained current–voltage (I–V) data [23] were used to modify the IK1 formula-
tions for WT, WT-D172N and D172N conditions. This was achieved by simulating the 
experimental voltage-clamp protocol [23], with which the experimental data [23] were 
fitted to model equations by using the Broyden-Fletcher-Goldfarb-Shanno optimiza-
tion algorithm following our previous study [10]. Relative current proportions for WT, 
WT-D172N and D172N conditions were scaled by using relative proportions of peak 
IKir2.1 [23]. The peak IKir2.1 was 4.6-fold for the D172N condition and 2.2-fold for the 
WT-D172N condition than that for the WT condition [23]. In simulations, Eq.  1 was 
modified to incorporate the D172N-induced changes in the channel kinetic properties, 
including (i) the marked augmentation of an outward Kir2.1 current through the D172N 
channel, and (ii) the rightward voltage shift of the peak repolarization current. The 
modified IK1 formulations for WT, WT-D172N and D172N conditions [10] are shown in 
Additional file 1.
A simple pore block theory [24] was used in this study to model the drug/ion channel 
interactions. With this theory, the effect of a drug on blocking an ion channel can be 
simulated using a blocking factor θ that reduces the maximal conductance of an ionic 
current is modified in a dose-dependent manner such that:
where [D] is the concentration of a drug,  IC50 is the half maximal inhibitory concentra-
tion, and nH is the Hill coefficient. The respective reduction of ionic currents in the pres-
ence of amiodarone was determined by using  IC50 and nH values as shown in Table 1. 
In this study, two concentrations of amiodarone in the effective therapeutic range were 
chosen. The range of clinical therapeutic concentrations is between 1 μM (low concen-
tration) and 3 μM (high concentration) [25, 26]. The resulting ion channel conductivity 










Table 1 Inhibition of cardiac ion currents in the presence of amiodarone
Data used in this study showing inhibition of ion currents in the presence of amiodarone. Half-maximal inhibitory 
concentration  (IC50) and Hill coefficient (nH) values for amiodarone extracted from literatures
Drug Amiodarone
Current IKr INa INaK ICaL INaCa IKs
IC50 (µM) 2.80 4.84 15.60 5.80 3.30 3.84
nH 0.91 0.76 1.00 1.00 1.00 0.63
Source [27] [28] [29] [30] [31] [32]
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Single‑cell model and AP simulations
In this study, the modified IK1 model was incorporated into the ten Tusscher et al. [21] 
model for the human ventricular cell AP. In the single cell AP model, the electrophysi-
ological activity during different phases can be described by the following equation:
where V is the transmembrane voltage, t is time, Cm is the cellular capacitance per unit 
surface area, Istim is the external stimulus current, and Iion is the sum of transmembrane 
ionic currents. The component of the late sodium current (INaL) from the ORd model 
[33] was incorporated. The physical units are as follows: time t is in ms, potential V is in 
mV, current Iion and externally applied stimulus current Istim are in pA, current densities 
are in pA/pF, capacitance Cm is in μF/cm2, channel conductance G is in nS/pF, intra- 
and extracellular ionic concentrations are in millimolar. The code for the cell model was 
downloaded from http://www-binf.bio.uu.nl/khwjtuss/SourceCodes/. The cell model 
was paced with an S1–S2 protocol. An S1 was applied with a basic cycle length (BCL) 
of 800 ms and an amplitude of −52 pA/pF for 1 ms. An S2 with the same amplitude and 
duration as the S1 was applied after the AP evoked by S1. AP model was stimulated by 
the application of pulses of a 1.25 Hz frequency, which roughly corresponds to 75 bpm 
of normal human heart. Equation 3 was integrated by using the forward Euler method 
with a time step of 0.02 ms. The Hodgkin–Huxley (HH) equations for the gating vari-
ables of the various time-dependent currents including the modified IK1 in the ten Tus-
scher et al. model were integrated using the Rush and Larsen scheme [34].
Tissue simulations
Initiation and conduction of APs in the multicellular tissue model were modeled with 
the following equation:
where D is the diffusion coefficient between ventricular cells describing the tissue’s elec-
trical conductivity, and ∇ is the gradient operator.
For one-dimensional (1D) simulations, a single fiber model of transmural strand with 
a length of 15  mm was used (discretized into 100 nodes). The total length is close to 
the normal range of the human transmural ventricle wall thickness of ~4.0 to 14.0 mm 
[35]. The fiber employed a spatial resolution of 0.15 mm, with each node representing 













+∇ · (D∇V )
Table 2 Ion channel conductivities (% of original value) in the presence of amiodarone
Ion channel conductivities (% of original value) in the presence of amiodarone. Definition of amiodarone concentrations: 
low (1 μM) and high (3 μM)
Conductivity Amiodarone
GKr GNa PNaK GCaL PNaCa GKs
Low dose (1 µM) 71.28 76.33 93.98 85.29 76.74 69.42
High dose (3 µM) 48.41 58.78 83.87 65.91 52.38 53.73
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ENDO, MIDDLE and EPI cells (with respective proportions of 25%: 35%: 40%). The 
lengths of each region were 3.75, 5.25 and 6 mm for ENDO, MIDDLE and EPI, respec-
tively. These proportions and the total length are similar to those used in other studies 
[10, 36–38]. The diffusion coefficient, D was set at 0.0008 cm2/ms giving a conduction 
velocity (CV) of 52 cm/s through the fiber, which is relatively close to the experimental 
CV of ~50 cm/s [39, 40]. In the model, a fivefold decrease in gap junctional conduct-
ance between the EPI and MIDDLE region was implemented. This followed the study of 
Gima and Rudy [41], which was based on experimental work of Yan et al. [35] showing 
a sharp transition in the tissue resistance in a left ventricular wedge, implying reduced 
electrical coupling in this region [42].
The pseudo-ECG was computed as an integral of the spatial gradient of transmem-
brane potential of cells at all positions on the fiber from an electrode by using [41]:
where ∅e is the computed potential at the electrode, α is the radius of the strand, r is the 
Euclidean distance from a source point x to the electrode point x′, and dx is the spatial 
resolution. In this study, we placed the electrode at a position 2.0 cm from the ENDO 
end of the strand, which resulted in a negative QRS and a positive T wave in the pseudo-
ECG waveforms. These waveforms were in concordance with the clinical data [2]. The 
QT interval was computed as the time interval determined by the definition of the onset 
of the QRS complex (Qonset = 0.0 mV, t = 0 ms) and the point at which the end of the 
T-wave (Tend) crossed the baseline. The time at which the ECG signal fell below a thresh-
old (Vthresh = 0.01 mV) was defined as Tend.
For two-dimensional (2D) simulations, an idealized geometry was implemented. The 
idealized geometry was a simple sheet of tissue measured 15 mm by 75 mm. It was mod-
eled by expanding the 1D fiber (100 cells, 15 mm in the x-direction) into a sheet with 
a width of 75 mm in the y-direction. The spatial resolution in both x and y directions 
was the same as used in the 1D fiber. In the 2D sheet tissue, re-entry was initiated by 
an S1-S2 stimulation protocol. A planar wave was initiated at the ENDO end by an S1 
stimulus (amplitude: −52 pA/pF, duration: 1 ms). During the vulnerable window, an S2 
stimulus with the same amplitude and duration as the S1 was applied to the junction of 
the EPI to MIDDLE cells. This action led to the initiation of a re-entrant excitation wave 
that then rotated through the tissue. However, the S2 had variable spatial sizes (width 
0.45 mm, length varies between 0 and 75 mm). A S2 stimulus with sufficient spatial size 
(S2 size) in 2D tissue is required to provide an adequate re-entrant pathway, which is 
dependent on the wavelength (wavelength = ERP × CV) of re-entry. In order to evalu-
ate the critical size of the re-entrant pathway, we estimated the minimum length of S2 
stimulus. The minimum length was measured as the smallest length which supported 
the formation of re-entry by decreasing it from 75 to 0 mm with decrement of 0.15 mm. 
This minimum length gives an indication of the susceptibility of the tissue to sustain re-
entry, i.e., the larger the minimum length, the more difficult for the initiation of re-entry 
[37]. For such an initiated re-entrant excitation waves, effects of amiodarone on their 
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Results
Effects of amiodarone on SQT3 in the cell model
Figure 2 shows the results of simulated current–voltage (I–V) for WT and mutant IK1 
channels. In simulations, IK1 was elicited by 400  ms depolarizing voltage steps from 
−120 to +20 mV and from a holding potential of −60 mV, with current traces for WT, 
WT-D172N and D172N IK1 current shown respectively in Fig. 2a–c. Figure 2d–f shows 
current–voltage (I–V) data for WT, WT-D172N and D172N conditions. The reversal 
potential of the I–V relations for WT and mutant (WT-D172N and D172N) IK1 were not 
significantly different. However, outward IK1 current differed markedly between WT and 
mutant channels: it was significantly greater for WT-D172N and D172N conditions than 
for WT condition. These features are consistent with those experimental data reported 
previously [2].
Changes in IK1 due to the KCNJ2 D172N mutation abbreviated human ventricular 
APD as shown in Fig. 3. Figure 3a–c shows AP waveforms V (mV) versus time t (ms). 
The measured  APD90 was 302, 406 and 304 ms for the ENDO, MIDDLE and EPI cell, 
respectively, in the WT condition, which were shortened, respectively, to 273, 357 and 
274 ms for the WT-D172N condition and to 261, 341 and 262 ms for the D172N condi-
tion. The abbreviated APD resulted from an increased IK1 during the AP repolarization 
phase as shown in Fig. 3d–f.
The effects of different doses of amiodarone on the AP characteristics for the human 
ventricular EPI cells are shown in Fig. 4a (WT-D172N condition) and b (D172N condi-
tion), and the corresponding  APD90 are plotted in Fig. 4c and d. The measured  APD90 
was prolonged from 275 ms in WT-D172N to 291 and 289 in the presence of low and 
high doses of amiodarone, respectively, and from 263  ms in D172N condition to 277 
and 273 ms in the presence of low and high doses of amiodarone. Additional simulations 
on ENDO and MIDDLE cells (data not shown) showed similar effects of amiodarone to 
those seen with the EPI ventricular AP waveform.
Fig. 2 Simulated current–voltage (I–V) relationships. a–c Currents traces for WT, WT-D172N and D172N IK1 
elicited by 400 ms depolarizing voltage steps from −120 to +20 mV and from a holding potential of −60 mV. 
d–f Current–voltage relationships. The current amplitude of the WT-D172N and D172N mutant conditions is 
significantly larger than that of the WT condition
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Rate-dependent effects of amiodarone on the APD of EPI cells was shown in Fig. 5a 
and b for the computed APD restitution (APD-R) curves for WT and mutation con-
ditions. Across the range of diastolic intervals (DI) studied, the measured  APD90 was 
increased in the presence of amiodarone. In addition, the APD-R relationships were 
attenuated by the action of amiodarone, as indicated by the decreased maximal slope 
of the APD-R curves (Fig. 5c, d). The measured ERP was also increased in the presence 
of amiodarone. The ERP reduction was also rate-dependent in Fig.  5e and f. Across a 
range of BCLs, the measured ERP in the presence of amiodarone was increased. Actions 
of amiodarone also attenuated the ERP-R curves, as indicated by the decreased maxi-
mal slope of the ERP-R curve (Fig. 5g, h) in the presence of amiodarone. As a decreased 
steepness of APD-R and ERP-R curves are believed to be associated with stability of re-
entry [43], indicating anti-arrhythmic effects of amiodarone on SQT3.
Effects of amiodarone on SQT3 in the 1D fiber model
Using a 1D-fiber model, a pseudo-ECG was computed for the WT, WT-D172N, D172N 
and actions of amiodarone conditions (Fig.  6). The results are shown in Fig.  6a, b, e 
and f for an excitation wave propagating from ENDO towards MIDDLE and EPI parts 
of the fiber. Amiodarone delayed the repolarization phase both in the WT-D172N and 
Fig. 3 Simulations of APs together with the corresponding time course and amplitude of IK1 in the WT, WT-
D172N and D172N conditions. a, d APs and IK1 for ENDO cells. b, e APs and IK1 for MIDDLE cells. c, f APs and IK1 
for EPI cells
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D172N conditions. These changes of the excitation wave were also reflected in the com-
puted pseudo-ECGs as shown in Fig.  6c, d, g and h for the WT-D172N, D172N and 
amiodarone-in-action conditions respectively. To quantify the effects, we calculated the 
QT intervals extracted from the simulation data (Fig.  6i–l). In simulations, the muta-
tion shortened APD, leading to abbreviated QT interval (322 ms for WT-D172N condi-
tion), which is similar to clinical observation (315 ms for the proband and 320 ms for her 
father) [2]. The simulated mutation produced a taller T-wave amplitude, which is also 
similar to clinical observation [2]. The pseudo-ECGs show an increment in the QT inter-
val in the presence of low and high doses of amiodarone, which changed from 322 ms 
in the WT-D172N condition to 341 and 340 ms, respectively. For the same condition, 
the QT interval was prolonged from 308 ms in the D172N condition to 325 and 324 ms, 
respectively. These QT intervals were prolonged, but were not within the normal physi-
ological range (from 360 to 440 ms). The simulated small QT interval prolongation was 
consistent with the clinical study [18] in which the patient remained short QT after use 
of amiodarone. T-wave amplitude in the presence of amiodarone under WT-D172N and 
D172N conditions was decreased as shown in Fig. 6i and k.
An increase in T-wave amplitude during simulated SQTS has been attributed to an 
increased spatial gradient in membrane potential [36, 37] and an inverse effect might 
explain the decrease T-wave amplitude seen in Fig. 6 of this study. Therefore, we exam-
ined effects of amiodarone on the membrane potential heterogeneity (δV) which was 
calculated as the difference between APs among three cell types. Via cell-to-cell electri-
cal interaction, δV (in the temporal domain) is smoothed in space producing a spatial 
gradient ∇V (in the spatial domain), which contributes to the computed pseudo-ECG as 
described in Eq. 4. Figure 7a and b show simulated ENDO, MIDDLE and EPI APs with 
Fig. 4 Effects of low and high doses of amiodarone on human ventricular EPI cell. a, c APs under the WT-
D172N condition in the presence of amiodarone, and corresponding  APD90 histogram. b, d APs under the 
D172N condition in the presence of amiodarone, and corresponding  APD90 histogram
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WT-D172N and WT-D172N +  low amiodarone conditions whilst Fig. 7c and d show 
corresponding time-course plots of the δV during APs between ENDO, MIDDLE and 
EPI cells. The maximal δV between both ENDO-MIDDLE and MIDDLE-EPI APs was 
smaller with the use of amiodarone than before (Fig. 7e, f ). The actions of amiodarone 
also augmented  APD90 dispersion in the fiber model with the electrotonic interaction 
Fig. 5 Rate-dependent APD restitution curves and ERP restitution curves for EPI cells under the WT, WT-
D172N and D172N conditions, and in the presence of amiodarone. a, b APD restitution curves under the 
WT-D172N and D172N conditions, respectively. c, d Measured slopes of APD restitution curves under the 
WT-D172N and D172N conditions, respectively. e, f ERP restitution curves under the WT-D172N and D172N 
conditions, respectively. g, h Measured slopes of ERP restitution curves under the WT-D172N and D172N 
conditions, respectively
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between cells. Figure  7g shows the spatial distribution of  APD90 for WT, WT-D172N 
and amiodarone-in-action conditions. The absolute spatial gradient of  APD90 was 
found to be augmented, as shown in Fig. 7h. The maximal gradient across the 1D fiber 
was smaller with the use of amiodarone than before (Fig.  7i, j). The D172N mutation 
augmented the APD dispersion at the junction region between the MIDDLE and EPI 
regions, whilst amiodarone attenuated the APD dispersion across the 1D strand, which 
also led to the decreased T-wave amplitude.
Simulations were also performed to determine whether or not amiodarone decreased 
susceptibility of tissue to ventricular arrhythmogenesis. Using a 1D fiber model we 
quantified tissue’s temporal vulnerability to unidirectional conduction in response to a 
premature stimulus for the amiodarone-in-action condition. Figure 8a–c shows the con-
ditioning excitation wave and the response of the tissue to a premature stimulus applied 
at ENDO part of the fiber (marked by the arrow). In Fig. 8a, the premature stimulus was 
applied early (i.e., at time = 335 ms after the previous excitation wave) so that the tissue 
surrounding the stimulus site did not have enough time to recover for re-excitation to 
occur. As a consequence, a bidirectional block was observed. In Fig. 8b, the premature 
stimulus was applied within the vulnerable window (at time = 341.5 ms) that produced 
a unidirectional conduction block. In Fig. 8c, the premature stimulus was applied after 
the vulnerable window (at time = 350 ms) and, consequently, bidirectional conduction 
was observed. Figure 8g and h show the width of the vulnerable window during which 
a premature stimulus applied at the ENDO part of the fiber resulted in the unidirec-
tional block under WT, WT-D172N, D172N and amiodarone-in-action conditions. 
Fig. 6 Space–time plot of AP propagation along a 1D fiber and the pseudo-ECGs. a, b Color mapping of 
membrane potential of cells in the WT-D172N and a low dose of amiodarone conditions, respectively. Space 
runs vertically from the ENDO end at the top to the EPI end at the bottom. Time runs horizontally (left to right). 
c, d The corresponding pseudo-ECGs derived from the propagating excitation wave for the WT-D172N and 
a low dose of amiodarone conditions, respectively. e, f Color mapping of membrane potential of cells in the 
D172N and a low dose of amiodarone conditions, respectively. g, h The corresponding pseudo-ECGs derived 
from the propagating excitation wave for the D172N and a low dose of amiodarone conditions, respectively. 
i, k Superimposed pseudo-ECGs for the WT-D172N and D172N conditions, respectively. j, l Associated QT 
intervals
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Fig. 7 Membrane potential heterogeneity (δV) between single ENDO, MIDDLE and EPI cells and transmural 
 APD90 distribution and its spatial gradient in 1D fiber model for the WT, WT-D172N, D172N and amiodarone-
in-action conditions. a, b ENDO, MIDDLE and EPI APs in WT-D172N and WT-D172N + low amiodarone 
conditions. c, d Corresponding plots of δV against time for the two conditions. Horizontal dashed lines mark 
peak ENDO-MIDDLE and MIDDLE-EPI δV in WT-D172N condition. e, f Maximal δV observed during repolariza-
tion (ENDO-MIDDLE) under WT-D172N and D172N conditions in the presence of amiodarone, respectively. 
Horizontal dashed lines mark peak ENDO-MIDDLE δV in WT condition. g Spatial distribution of  APD90 on 1D 
fiber model in WT, WT-D172N and amiodarone-in-action conditions. h Spatial gradient of  APD90 on 1D fiber 
model in WT, WT-D172N and amiodarone-in-action conditions. i, j The maximal spatial gradient of  APD90 
under WT-D172N and D172N conditions in the presence of amiodarone, respectively
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Simulations were also performed in which the premature stimulus was applied to the 
EPI rather than the ENDO part of the fiber (Fig. 8d–f). Figure 8d–f represent bidirec-
tional conduction block (at time = 332 ms), unidirectional block (at time = 340 ms) and 
bidirectional conduction (at time = 350 ms). Effects of amiodarone on temporal vulner-
ability in WT-D172N and D172N mutations are shown in Fig. 8i and j. These simulation 
results show clearly that the tissue’s temporal vulnerability is decreased by amiodarone.
Effects of amiodarone on SQT3 in the 2D tissue model
Using an idealized 2D sheet model, we proceeded to measure the minimum spatial 
size of a premature S2 stimulus that provides a sufficient substrate size for sustaining 
re-entry initiated for SQT3 and amiodarone-in-action conditions. Results are shown in 
Fig. 9, in which patterns of re-entrant excitation waves are represented via pseudo-color 
mapping of transmembrane voltage. During the simulation, the S1 stimulus was applied 
to the ENDO end to evoke a planer excitation wave that propagated towards the MID-
DLE and EPI regions (Fig. 9a, f, k). After a time delay (WT: 340 ms; WT-D172N: 312 ms; 
WT-D172N + low amiodarone: 325 ms), a S2 stimulus was applied to the MIDDLE-EPI 
junction region that produced a unidirectional conduction, forming a re-entrant excita-
tion wave (Fig. 9b, g, l). The induced re-entrant excitation self-terminated for the WT 
condition (Fig. 9c–e), but sustained for the WT-D172N mutation condition (Fig. 9h–j). 
It is attributable to the shortening of APD due to the mutation, decreasing the wave-
length of the ventricular excitation wave. With the use of amiodarone, re-entrant excita-
tion wave self-terminated as shown in Fig. 9m–o. Figure 9p–r show a recording of the 
evolution of the AP of an EPI cell in the 2D sheet model under the WT, WT-D172N 
and low dose of amiodarone conditions, respectively. The measured minimum spatial 
length of S2 stimulus required for re-entry under WT-D172N and D172N conditions in 
Fig. 8 Space–time plots of propagating conditioning excitation wave and response of the tissue to a prema-
ture stimulus in the WT condition. Membrane potentials of cells are mapped onto a color spectrum. Space 
runs vertically from the ENDO end at the top to the EPI end at the bottom. Time runs horizontally (left to right). 
a–c, g, h Premature stimulus applied at ENDO part at: a 335 ms, bidirectional block. b 341.5 ms, unidirectional 
block. c 350 ms, bidirectional conduction. g Vulnerability of the tissue in WT-D172N and amiodarone-in-
action conditions. h Vulnerability of the tissue in D172N and amiodarone-in-action conditions. d–f, i, j Pre-
mature stimulus applied at EPI part at: d 332 ms, bidirectional block. e 340 ms, unidirectional block. f 350 ms, 
bidirectional conduction. i Vulnerability of the tissue in WT-D172N and amiodarone-in-action conditions. j 
Vulnerability of the tissue in D172N and amiodarone-in-action conditions
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the presence of amiodarone is shown in Fig. 9s and t, respectively. Prolongation of APD 
due to the actions of amiodarone increased the wavelength of the ventricular excitation 
wave, and thus increased the minimal length of S2 stimulus. This result supports the 
notion that in SQT3 tissue with the use of amiodarone, re-entrant excitation waves is 
less likely to occur.
Discussion
Summary of the major findings
The proband in whom the KCNJ2 D172N mutation was identified was heterozygotic for 
the SQT3 mutation (WT-D172N) [2]. She had a QTc interval of 315 ms, whereas her 
father had a QTc interval of 320 ms [2]. It is of particular note that with the use of ami-
odarone in the WT-D172N condition, mimicking the effects on the heterozygous state 
of the proband, we found that the simulated QT interval extended from 322 to 341 ms 
in the low-dose amiodarone condition and 340  ms in the high-dose condition. The 
QT interval extended from 308 ms in the D172N condition to 325 ms in the low-dose 
amiodarone condition and 324 ms in the high-dose condition. In addition, the risk of 
arrhythmogenesis as measured by the vulnerability of tissue was decreased in the pres-
ence of both low and high doses of amiodarone. Our simulation results indicate that the 
amiodarone (i) extended the  APD90 in the SQT3 condition and decreased susceptibility 
to arrhythmia; (ii) extended the QT interval on the pseudo-ECG and reduced the T-wave 
amplitude; (iii) decreased the maximal voltage heterogeneity (δV) during APs, which 
contributed to the decreased T-wave amplitude; (iv) prolonged cell  APD90 across the 1D 
strand and decreased maximal dispersion of  APD90, which also subsequently led to the 
decreased T-wave amplitude; (v) prevented re-entrant excitation waves and increased 
the minimum substrate size of tissue required to maintain re-entrant excitation waves. 
Fig. 9 Snapshots of initiation and conduction of re-entrant excitation wave in a 2D model of transmural 
ventricle tissue under the WT, WT-D172N and amiodarone-in-action conditions. a, f, k A planar wave gener-
ated by S1 stimulus at the ENDO end, which propagates towards the MIDDLE and EPI regions. Snapshots 
at time = 10 ms. b, g, l S2 was applied to the MIDDLE-EPI junction region during the vulnerable window 
of the tissue. c, h, m Developed re-entrant excitation waves. d, i, n Developed re-entrant excitation waves. 
Snapshots at time 650 ms. e, j, o Snapshots of the re-entrant excitation waves. Re-entry was prevented in the 
presence of amiodarone. Snapshots at time 1500 ms. p, q, r Evolution of the AP of an EPI cell under the WT, 
WT-D172N and WT-D172N + low amiodarone conditions, respectively. s, t The measured minimum spatial 
length of S2 that provides a sufficient substrate for the formation of a re-entrant circuit under WT-D172N and 
D172N conditions in the presence of amiodarone, respectively
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These changes due to the presence of amiodarone indicated its anti-arrhythmic effects in 
SQT3 condition.
Relevance of the study
SQT3 produces changes on the QT interval and T-wave, caused by a shortening of total 
repolarization time, which are in agreement with the previous studies [2, 10]. Those 
studies investigated the IK1 current underlying the changes in the pseudo-ECG caused by 
a D172N mutation in the SQT3 condition. However, the present study first assessed the 
pharmacological effect of amiodarone on ventricular excitation associated with SQT3. 
Our simulations were able to reproduce the known effects of D172N mutation on the 
electrophysiological activity of the ventricles as shown in the literature [2], which pro-
vide the first step towards the validation of the use of the cardiac models in assessing the 
effects of amiodarone on SQT3.
Significance of the study
Our simulations showed the anti-arrhythmic effects of amiodarone on SQT3. This was 
done by thoroughly analyzing the functional effects of amiodarone at the cell and tissue 
levels. First, the action of amiodarone was simulated by using a single pore block theory, 
as in the previous studies [44, 45]. Then, the effects of amiodarone were investigated in a 
1D ventricular model, using which pseudo-ECGs were simulated. Finally, effects of ami-
odarone on re-entrant excitation wave dynamics in SQT3 condition were quantitatively 
assessed. Our results showed that both of low and high doses of amiodarone exhibited 
anti-arrhythmic effects for SQT3.
The results demonstrated that the presence of amiodarone led to QT interval prolon-
gation and a reduction in the T-wave amplitude. As expected, the QT interval prolonga-
tion is explained by an APD prolongation, whereas the decrease in the T-wave amplitude 
correlates with reduced dispersion in repolarization as demonstrated by decreased dis-
persion of the  APD90 across the 1D fiber model.
In the SQT3 setting, ventricular fibrillation could be elicited by programmed electri-
cal stimulation. It was hypothesized that APD and ERP abbreviation are factors contrib-
uting to an increased risk of re-entrant arrhythmias. Amiodarone prevented re-entrant 
excitation waves. This is attributable to the APD prolongation, which increased the 
wavelength of excitation waves, and therefore, increased the critical mass of tissue nec-
essary to accommodate re-entrant excitation waves, suppressing the maintenance of re-
entrant excitation waves. Thus, re-entrant excitation wave in the presence of amiodarone 
becomes more difficult to be initiated and sustained. This simulation result was consist-
ent with no further syncope or palpitations in clinical study [18].
In this study, due to the scarcity of accurate experimental models of SQT3 and of 
in vitro pharmacological data of SQT3, we are currently unable to compare our simula-
tion results with experiments for validation. However, we used the well-established ten 
Tusscher et al. [21] model for simulating human ventricular APs along with the recent 
SQT3 IK1 model developed by our group [10]. These models were validated previously. 
With regard to amiodarone effects, although there are no direct experimental data for 
us to compare, results from the clinical study [18] have demonstrated the beneficial 
effects of amiodarone on SQTS patients. Our simulation data are in accordance with the 
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clinical phenomenon [18], indicating the anti-arrhythmic effect of amiodarone in SQT3 
condition.
Limitations of the study
Limitations of the ten Tusscher et al. [21] model have been discussed in detail elsewhere. 
Although such a model is not as complete as the newest models [33], it is sufficient for 
the purpose of this study as the simulated effect of amiodarone on SQT3 is in accord-
ance with the clinical phenomenon [18]. The biophysical approach, which we adopt here, 
has also been used by several other groups (see, e.g. [38, 46, 47]).
Although we considered intercellular electrical coupling with each distinct cell type, 
the 1D and 2D idealized models cannot represent a realistic anatomical structure, which 
might influence the maintenance of ventricular arrhythmias. The structure of realistic 
anatomical tissue is much more complex than the idealized isotropic tissue studied here 
[48]. The idealized model, which was used to simulate re-entrant excitation waves, lacks 
inclusion of Purkinje fibers, which may play a significant role in arrhythmogenesis in 
SQTS. Furthermore, the model did not consider the effect of the atria, mechano-elec-
tric coupling and feedback, tissue deformation and coronary flow, which feasibly might 
influence re-entrant excitation waves.
Regarding the experimental conditions, many factors that may affect the binding of 
a drug to ion channels are increasingly being modeled, including oxygen, the concen-
tration of ions, temperature and pH [49]. However, pharmaceutical screening does not 
usually record sufficient data to evaluate the dynamic changes caused by drugs [45]. For 
conditions with variable pacing rates, conductance block approximation may be insuf-
ficient for simulation of realistic amiodarone actions.
Another limitation is the use of data from animal models instead of human to math-
ematically describe the effects of amiodarone on the ionic currents as listed in Table 1. 
Limitations of data from animal models of disease in nonclinical safety testing include 
a lack of historical control, heterogeneity in disease expression, a limited life span and 
confounding effects of the disease. However, little information is known about the effects 
of amiodarone on the specific ionic currents in human. Therefore, for future work, inte-
gration of experimental data for the different ion channels of human heart acquired at 
body temperature when become available could provide a better insight into the effects 
of amiodarone on SQT3.
Conclusions
In this study, we presented a simulation study showing the effects of amiodarone on 
SQT3. It was shown that amiodarone altered the profiles of APs and pseudo-ECGs, as 
well as the dynamics of re-entrant excitation waves. Amiodarone produced QT inter-
val prolongation (owing to APD prolongation), decreased APD dispersion and mem-
brane potential dispersion (δV), which contributed to the decreased T-wave amplitude. 
Additionally, amiodarone increased ERP, reduced vulnerable window and prevented re-
entrant excitation waves. Our results demonstrate anti-arrhythmic effects of amiodar-
one on SQT3 and suggest that amiodarone may be a potential pharmacological agent for 
treating SQT3 patients.
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